cancer immunology, immunotherapy : cii

[1] Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11-13 2018, Milan, Italy.

[2] Comparative Analysis of Blood and Bone Marrow for the Detection of Circulating and Disseminated Tumor Cells and Their Prognostic and Predictive Value in Esophageal Cancer Patients

[3] the fibroblast growth factor receptors in breast cancer: from oncogenesis to better treatments

[4] Advances and challenges in targeted therapies for HER2-amplified colorectal cancer.

[5] Patent landscape of molecular and cellular targeted therapies for recessive dystrophic epidermolysis bullosa.

[6] [Treatment of hand-foot syndrome in the context of targeted therapies].

[7] Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.

[8] Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias

[9] signal-targeted therapies and resistance mechanisms in pancreatic cancer: future developments reside in proteomics

[10] adult-onset still’s disease: from pathophysiology to targeted therapies

[11] advances of targeted therapies in non-small cell lung cancer

[12] obesity-related asthma: immune regulation and potential targeted therapies

[13] overall survival in renal cell carcinoma after introduction of targeted therapies: a norwegian population-based study

[14] bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms

[15] Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?

[16] Advances and challenges in targeted therapies for HER2-amplified colorectal cancer.